Next Article in Journal
Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants
Previous Article in Journal
Diagnosis of Dengue Infection Using Conventional and Biosensor Based Techniques

Perspective of Use of Antiviral Peptides against Influenza Virus

Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno CZ-613 00, Czech Republic
Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ-616 00, Czech Republic
Wool and Knitting Research Institute, Brno, Sujanovo namesti 3, Brno CZ-602 00, Czech Republic
Laboratory of Tumour Biology, Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Libechov CZ-277 21, Czech Republic
Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovak Republic
Author to whom correspondence should be addressed.
Academic Editor: Alexander Ploss
Viruses 2015, 7(10), 5428-5442;
Received: 21 July 2015 / Revised: 22 September 2015 / Accepted: 30 September 2015 / Published: 20 October 2015
(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
The threat of a worldwide influenza pandemic has greatly increased over the past decade with the emergence of highly virulent avian influenza strains. The increased frequency of drug-resistant influenza strains against currently available antiviral drugs requires urgent development of new strategies for antiviral therapy, too. The research in the field of therapeutic peptides began to develop extensively in the second half of the 20th century. Since then, the mechanisms of action for several peptides and their antiviral prospect received large attention due to the global threat posed by viruses. Here, we discussed the therapeutic properties of peptides used in influenza treatment. Peptides with antiviral activity against influenza can be divided into three main groups. First, entry blocker peptides such as a Flupep that interact with influenza hemagglutinin, block its binding to host cells and prevent viral fusion. Second, several peptides display virucidal activity, disrupting viral envelopes, e.g., Melittin. Finally, a third set of peptides interacts with the viral polymerase complex and act as viral replication inhibitors such as PB1 derived peptides. Here, we present a review of the current literature describing the antiviral activity, mechanism and future therapeutic potential of these influenza antiviral peptides. View Full-Text
Keywords: cationic peptides; hemagglutinin; influenza virus; membrane fusion; neuraminidase; viral replication cationic peptides; hemagglutinin; influenza virus; membrane fusion; neuraminidase; viral replication
Show Figures

Graphical abstract

MDPI and ACS Style

Skalickova, S.; Heger, Z.; Krejcova, L.; Pekarik, V.; Bastl, K.; Janda, J.; Kostolansky, F.; Vareckova, E.; Zitka, O.; Adam, V.; Kizek, R. Perspective of Use of Antiviral Peptides against Influenza Virus. Viruses 2015, 7, 5428-5442.

AMA Style

Skalickova S, Heger Z, Krejcova L, Pekarik V, Bastl K, Janda J, Kostolansky F, Vareckova E, Zitka O, Adam V, Kizek R. Perspective of Use of Antiviral Peptides against Influenza Virus. Viruses. 2015; 7(10):5428-5442.

Chicago/Turabian Style

Skalickova, Sylvie, Zbynek Heger, Ludmila Krejcova, Vladimir Pekarik, Karel Bastl, Jozef Janda, Frantisek Kostolansky, Eva Vareckova, Ondrej Zitka, Vojtech Adam, and Rene Kizek. 2015. "Perspective of Use of Antiviral Peptides against Influenza Virus" Viruses 7, no. 10: 5428-5442.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop